Related Experiment Video
Updated: Jun 14, 2025
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Targeting Glioblastoma Stem Cells via EphA2: Structural Insights into the RNA Aptamer A40s for Precision Therapy
Isidora Diakogiannaki1, Vincenzo Maria D'Amore1, Alessandra Affinito2
1Department of Pharmacy, University of Naples Federico II, Via Domenico Montesano 49, 80131 Naples, Italy.
Abstract:
EphA2 receptor tyrosine kinase is overexpressed in many solid tumors and serves as a key driver of tumorigenesis and metastasis. It is highly expressed in glioblastoma multiforme, the most aggressive brain tumor in adults, and in its stem cells [glioblastoma stem cells (GSCs)], which contribute to treatment resistance and tumor relapse. In a previous study, we used the Systematic Evolution of Ligands by Exponential Enrichment (SELEX) procedure, a method for selecting high-affinity nucleic acids to specific targets via iterative selection and amplification, to identify the 2'-fluorinated EphA2-targeting RNA aptamer A40L and a truncated 30-mer derivative, A40s. Both aptamers were able to inhibit GSC growth, stemness, and migration upon EphA2 binding. Here, by integrating computational and experimental methods, the A40s structure was unraveled and its interaction with EphA2 was investigated. Our model offers a blueprint to accelerate the development of optimized A40s variants, advancing next-generation EphA2-targeted anticancer therapies.
Insights
Researchers elucidated the structure of the A40s RNA aptamer, which targets the EphA2 receptor tyrosine kinase. This finding advances the development of novel therapies for glioblastoma stem cells and other cancers.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- EphA2 receptor tyrosine kinase is overexpressed in solid tumors, driving tumorigenesis and metastasis.
- EphA2 is highly expressed in glioblastoma stem cells (GSCs), contributing to treatment resistance and relapse.
Purpose of the Study:
- To unravel the structure of the A40s RNA aptamer targeting EphA2.
- To investigate the interaction between A40s and EphA2.
- To provide a blueprint for developing optimized A40s variants for cancer therapy.
Main Methods:
- Systematic Evolution of Ligands by Exponential Enrichment (SELEX) to identify aptamers.
- Computational and experimental methods to determine aptamer structure.
- Biochemical assays to study aptamer-target interactions.
Main Results:
- The 30-mer RNA aptamer A40s targets the EphA2 receptor.
- A40s inhibits glioblastoma stem cell growth, stemness, and migration.
- A structural model of A40s-EphA2 interaction was developed.
Conclusions:
- The elucidated A40s structure and EphA2 interaction model facilitate the design of improved aptamers.
- This research advances next-generation EphA2-targeted anticancer therapies.
More Related Videos
10:46A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
09:40Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
